ClinicalTrials.gg
CompletedNCT06723782Updated Oct 6, 2026

Surgical Release of Hand Tendons With Wrapping of the Released Tendon Using an Amniotic Membrane

A Phase 2 interventional study of AMTRIX-D in Tendon Adhesion and Tenolysis, sponsored by TBF Genie Tissulaire. Completed at 1 site in France. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by TBF Genie Tissulaire · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Feb 2024, registered Dec 2024).
Updated Oct 6, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓
Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate whether an amniotic membrane can function as an effective anti-adhesive barrier following surgical release of tendon adhesions. The main question the clinical trial aims to answer is:

- Can wrapping an amniotic membrane around a surgically released tendon help reduce recurrence of adhesions and promote recovery of hand functionality?

Participants will:

  • Undergo surgical treatment (surgical release of the tendon adhesions and wrapping of the amniotic membrane around the release tendon) on Day 0.
  • Visit the center for a series of tests 15 days, 6 weeks, 3 months, 6 months after the surgical intervention.
Read the detailed description

Tendon adhesions are a common problem in hand injuries and can have multiple causes. They can occur as a result of tendon damage itself or in the absence of such damage, following a fracture, crush injury, or infection. During healing, tendons become surrounded by an inflammatory exudate rich in fibrin, which can later turn into scar tissue. This scar tissue forms a strong bond between the tendon and the surrounding tissue, leading to significant functional impairment.

In their epidemiological study of 5,229 flexor tendon repairs, Dy et al. determined that 6% of patients who had undergone primary repair required a second intervention, with surgical release of adhesions around the tendons in 58% of cases. In flexor tendon repairs, adhesions are particularly promoted by damage to the tendon sheath, poor junction of the two severed ends of a lacerated tendon, or ischemia of the tendon and immobilization. Regardless of the etiology, adhesions prevent the efficient gliding of the tendon within its sheath, resulting in a discrepancy between near-normal passive range of motion and limited active range of motion.

When the range of motion deficit persists despite 6 months of high-quality rehabilitation, surgical treatment is considered. Tenolysis and early mobilization are the standard treatments for symptomatic tendon adhesions in the hand. Tenolysis involves surgically releasing the adhesions formed around the tendons. Follow-up rehabilitation after tendon surgical release can help reduce adhesion formation, though it does not completely prevent their formation or recurrence after tenolysis.

In recent years, many strategies have been proposed to limit adhesion formation after tendon repair surgery in the hand, or recurrence after tenolysis. Tested physical barriers include, among others, the interposition of an amniotic membrane or a composite of hyaluronic acid and methylcellulose, local application of sodium hyaluronate or various gels derived from proteoglycans or hyaluronan, or the use of non-steroidal anti-inflammatory drugs.

However, no definitive solution has yet been found, and to date, the use of anti-adhesion barriers remains limited in routine practice.

The product developed by TBF is set in this context with the goal of offering a safe biological solution that would minimize adhesion recurrence after tenolysis and promote the recovery of hand functionality.

02

Conditions studied

  • Tendon Adhesion
  • Tenolysis
03

In context

Lead sponsor

TBF Genie Tissulaire is the lead sponsor of 20 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Man or woman aged 18 to 65 years old
  • Adhesion of a flexor and/or extensor tendon of the hand.
  • Adhesion localized to a single finger.
  • Adhesion that has been present for at least 3 months following primary repair, despite high-quality rehabilitation. Primary repair is defined as the repair of a tendon injury, fracture, crush injury of the finger, infection, etc., leading to the adhesion of the tendon to surrounding tissue.
  • Patient with a total passive range of motion of the proximal and distal interphalangeal joints of at least 150°.
  • Informed and consenting patient.
  • Patient enrolled in a social security plan or a beneficiary of such a plan.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding woman, or without an effective method of .
  • Patient requiring tenolysis after tendon grafting for the reconstruction of a deep common flexor or after reimplantation.
  • Patient with amputated hand(s).
  • Patient with an untreated fracture or non-union in the affected hand.
  • Patient requiring multiple surgical interventions that may be potential confounding factors, particularly those involving additional incisions.
  • Patient unable to understand rehabilitation or follow the study protocol.
  • Patient with a to anesthesia.
  • Person deprived of liberty by judicial or administrative decision.
  • Adult subject to legal protection measures or incapable of expressing consent.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    AMTRIX-D

    Surgical release of the tendon and wrapping of the released tendon with desiccated amniotic membrane (AMTRIX-D)

    Biological: AMTRIX-D

Interventions

  • BiologicalAMTRIX-D

    Use of a decellularized, viro-inactivated, desiccated, and sterile allogeneic amniotic membrane graft to wrap a tendon after release of its adhesions.

06

What researchers measure

Primary outcomes

  1. Change in the finger total active range of motion

    Total active range of motion of the finger evaluated according to Strickland's classification: (TAM/175) × 100, where TAM = flexion of the proximal interphalangeal joint + flexion of the distal interphalangeal joint - extension deficit. Total active range of motion scores are expressed as percentages and classified into four categories: poor if \< 25%, moderate from 25% to 49%, good from 50% to 74%, and excellent if \> 75%. The primary objective of the study will be achieved if the total active range of motion is good or excellent (\>50%) at 6 months.

    Time frame: 6 months

Secondary outcomes

  1. Change in the daily functionality of the finger

    Daily functionality of the finger evaluated using Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire (0 = no disability, 100 = most severe disability).

    Time frame: 15 days, 6 weeks, 3 months, 6 months

  2. Change in finger pain

    Pain evaluated from 0 (no pain) to 10 (worst imaginable pain) on a visual analog scale (VAS).

    Time frame: 15 days, 6 weeks, 3 months, 6 months

  3. Change in hand grip strength

    Grip strength measured in kg by grip strength test using a hand dynamometer.

    Time frame: 6 weeks, 3 months, 6 months

  4. Frequency of occurrence of post-surgical complications

    Evaluation of the frequency of occurrence of post-surgical complications and in particular rupture of the deep common flexor tendon, phlegmon, wound dehiscence.

    Time frame: 15 days, 6 weeks, 3 months, 6 months

07

Study locations

1 site
  • Institut Chirurgical de la Main et du Membre Supérieur
    Lyon, 69006, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Recruiting→Completed
changed Oct 6, 2026
Primary completion
Aug 2026→Sep 16, 2026 (actual)
Oct 6, 2026
Study completion
Aug 2026→Sep 16, 2026 (actual)
Oct 6, 2026
Enrollment
16 (estimated)→18 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Recruiting→Completed
    Primary completion Aug 2026→Sep 16, 2026 (now actual)
    Study completion Aug 2026→Sep 16, 2026 (now actual)
    Enrollment 16 (estimated)→18 (actual)
    + 7 other changes: identifiers, verification date, oversight details, description, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06723782
Lead sponsor
TBF Genie Tissulaire
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Feb 15, 2024
Primary completion
Sep 16, 2026
Completion
Sep 16, 2026
Last update
Oct 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion